Jin Yang Pharmaceutical Co. Ltd (007370) - Total Assets
Based on the latest financial reports, Jin Yang Pharmaceutical Co. Ltd (007370) holds total assets worth ₩231.41 Billion KRW (≈ $156.82 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Jin Yang Pharmaceutical Co. Ltd shareholders equity for net asset value and shareholders' equity analysis.
Jin Yang Pharmaceutical Co. Ltd - Total Assets Trend (2014–2024)
This chart illustrates how Jin Yang Pharmaceutical Co. Ltd's total assets have evolved over time, based on quarterly financial data.
Jin Yang Pharmaceutical Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jin Yang Pharmaceutical Co. Ltd's total assets of ₩231.41 Billion consist of 19.1% current assets and 81.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.78 Billion | 0.8% |
| Accounts Receivable | ₩26.10 Billion | 11.5% |
| Inventory | ₩14.62 Billion | 6.4% |
| Property, Plant & Equipment | ₩43.49 Billion | 19.1% |
| Intangible Assets | ₩6.23 Billion | 2.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Jin Yang Pharmaceutical Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Jin Yang Pharmaceutical Co. Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jin Yang Pharmaceutical Co. Ltd's current assets represent 19.1% of total assets in 2024, a decrease from 58.7% in 2014.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 8.3% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 19.1% of total assets.
Jin Yang Pharmaceutical Co. Ltd Competitors by Total Assets
Key competitors of Jin Yang Pharmaceutical Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Jin Yang Pharmaceutical Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.52 | 2.11 | 1.69 |
| Quick Ratio | 0.35 | 1.34 | 1.23 |
| Cash Ratio | 0.00 | 0.16 | 0.00 |
| Working Capital | ₩-42.25 Billion | ₩23.01 Billion | ₩11.76 Billion |
Jin Yang Pharmaceutical Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Jin Yang Pharmaceutical Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.48 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 89.8% |
| Total Assets | ₩227.57 Billion |
| Market Capitalization | $41.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jin Yang Pharmaceutical Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jin Yang Pharmaceutical Co. Ltd's assets grew by 89.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jin Yang Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual total assets of Jin Yang Pharmaceutical Co. Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩227.57 Billion ≈ $154.22 Million |
+89.79% |
| 2023-12-31 | ₩119.91 Billion ≈ $81.26 Million |
+4.77% |
| 2022-12-31 | ₩114.44 Billion ≈ $77.56 Million |
+16.18% |
| 2021-12-31 | ₩98.50 Billion ≈ $66.75 Million |
+44.69% |
| 2020-12-31 | ₩68.08 Billion ≈ $46.13 Million |
-0.29% |
| 2019-12-31 | ₩68.28 Billion ≈ $46.27 Million |
-2.55% |
| 2018-12-31 | ₩70.06 Billion ≈ $47.48 Million |
-5.13% |
| 2017-12-31 | ₩73.85 Billion ≈ $50.05 Million |
-3.82% |
| 2016-12-31 | ₩76.78 Billion ≈ $52.04 Million |
-11.64% |
| 2015-12-31 | ₩86.90 Billion ≈ $58.89 Million |
+13.33% |
| 2014-12-31 | ₩76.68 Billion ≈ $51.97 Million |
-- |
About Jin Yang Pharmaceutical Co. Ltd
Jin Yang Pharmaceutical Co., Ltd. engages in the pharmaceutical business in South Korea. The company offers crivix tablets, Eszol tablets, atolan tablets, prescription drugs, and over-the-counter drugs. It also offers antilipidemic, antiplatelet, gastrointestinal, and respiratory agents; antithrombotics; NSAIDs; menopause symptoms treatment; and stomatological products. The company also exports i… Read more